CareLit · DOI-Nachweis · Pneumologie
Tiotropium + Olodaterol Fixed-Dose Combination Therapy Provides Lung-Function Benefits Compared With Tiotropium Alone In Patients With GOLD A/B And C/D Chronic Obstructive Pulmonary Disease: Post Hoc Analyses Of Two 1-Year Studies
DOI 10.1055/s-0036-1572057
Bibliografische Angaben
Nachweis in CareLit
Autor:innenT Glaab, R Buhl, R Abrahams, L Grönke, F Voss, M Flezar, GT Ferguson
ZeitschriftPneumologie
Ausgabe02/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Rationale: Tiotropium plus olodaterol (T+O) fixed-dose combination therapy combines the long-acting muscarinic antagonist tiotropium and the recently approved long-acting β2-agonist olodaterol as once-daily maintenance treatment in chronic obstructive pulmonary disease (COPD). We present post hoc analyses of data from the two pivotal 1-year TONADO studies that examined the lung-function benefits of T+O 5/5 µg (via R…
Zitieren
Zitierempfehlung
T Glaab, R Buhl, R Abrahams, L Grönke, F Voss, M Flezar, GT Ferguson (2016) Tiotropium + Olodaterol Fixed-Dose Combination Therapy Provides Lung-Function Benefits Compared With Tiotropium Alone In Patients With GOLD A/B And C/D Chronic Obstructive Pulmonary Disease: Post Hoc Analyses Of Two 1-Year Studies. Pneumologie (02). https://doi.org/10.1055/s-0036-1572057
Mit CareLit weiterarbeiten